Daiichi Sankyo, Novartis Gain MHLW Approval For Combination Hypertension Drugs
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Daiichi Sankyo Co. and Novartis Pharma KK received Ministry of Health, Labor and Welfare approval to manufacture and distribute in Japan hypertension treatment drugs that combine angiotensin receptor blockers and calcium channel blockers, the two companies announced Jan. 20